Key Insights

Highlights

Treatment Research

1 treatments under study, led by Brentuximab Vedotin Plus Chp

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07624838RecruitingPrimary

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Showing all 1 trials

Research Network

Common Treatments

  • Brentuximab Vedotin Plus Chp1

Active Sponsors

  • Takeda1
  • Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea1

Activity Timeline